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Abstract
Question
Do steroids improve neurologic symptoms in patients with
metastatic brain tumors compared to no treatment? If ste-
roids are given, what dose should be used? Comparisons
include: (1) steroid therapy versus none. (2) comparison of
different doses of steroid therapy.
Target population
These recommendations apply to adults diagnosed with
brain metastases.
Recommendations
Steroid therapy versus no steroid therapy
Asymptomatic brain metastases patients without mass effect
Insufﬁcient evidence exists to make a treatment recom-
mendation for this clinical scenario.
Brain metastases patients with mild symptoms related to
mass effect
Level 3 Corticosteroids are recommended to provide tem-
porary symptomatic relief of symptoms related to increased
intracranial pressure and edema secondary to brain metas-
tases. It is recommended for patients who are symptomatic
from metastatic disease to the brain that a starting dose of 4–
8 mg/day of dexamethasone be considered.
Brain metastases patients with moderate to severe symp-
toms related to mass effect
Level 3 Corticosteroids are recommended to provide
temporary symptomatic relief of symptoms related to
increased intracranial pressure and edema secondary to
brain metastases. If patients exhibit severe symptoms
consistent with increased intracranial pressure, it is rec-
ommended that higher doses such as 16 mg/day or more
be considered.
Choice of Steroid
Level 3 If corticosteroids are given, dexamethasone is the
best drug choice given the available evidence.
Duration of Corticosteroid Administration
Level 3 Corticosteroids, if given, should be tapered slowly
over a 2 week time period, or longer in symptomatic
patients, based upon an individualized treatment regimen
and a full understanding of the long-term sequelae of
corticosteroid therapy.
Given the very limited number of studies (two) which met
the eligibility criteria for the systematic review, these are
the only recommendations that can be offered based on this
methodology. Please see ‘‘Discussion’’ and ‘‘Summary’’
section for additional details.
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Rationale
Glucocorticoids have typically been used to assist in con-
trolling cerebral edema in the early supportive care of the
patient with newly diagnosed metastatic brain disease.
Dexamethasone is generally considered the steroid of
choice because of its minimal mineralocorticoid effect and
long half-life, although any other corticosteroid can be
effective if given in equipotent doses. Steroids have been
used alone for palliation of symptoms and in combination
with radiotherapy as an initial course of therapy. A review
of the available literature indicates that the majority of
these patients have been managed with starting doses of 4–
8 mg/day and it has been stated that up to 75% of patients
with brain metastases show marked neurological
improvement within 24–72 h after beginning dexametha-
sone [1]. However, side effects from chronic dexametha-
sone administration, including myopathy, are frequent and
contribute to disability. Asymptomatic or minimally
symptomatic patients may beneﬁt little from the routine
administration of steroid therapy and be exposed to these
toxicities. Although successful clinical experience would
lead to the conclusion that the role of steroids is ﬁrmly
established in the management of brain metastases, even a
cursory review of the literature will demonstrate signiﬁcant
variability in recommendations and a general lack of well-
controlled studies addressing this speciﬁc issue.
This systematic review addresses the role of cortico-
steroids in the treatment of metastatic brain disease with
the following overall objectives:
1. To systematically review the evidence available for the
following treatment comparisons for patients diag-
nosed with brain metastases speciﬁcally addressing the
following questions:
• Do steroids improve neurologic symptoms in
patients with metastatic brain tumors compared to
no treatment?
• If steroids are given, what dose should be used?
2. To make recommendations based on this evidence for
the role of corticosteroids in the management of these
patients.
Methods
Search strategy
The following electronic databases were searched from
1990 to September 2008: MEDLINE
 , Embase
 , Coch-
rane Database of Systematic Reviews, Cochrane Con-
trolled Trials Registry, and Cochrane Database of Abstracts
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123of Reviews of Effects. A broad search strategy using a
combination of subheadings and text words was employed.
The search strategy is documented in the methodology
paper for this guideline series by Robinson et al. [2].
Reference lists of included studies were also reviewed.
Eligibility criteria
• Published in English with a publication date of 1990
forward.
• Patients with brain metastases.
• Fully-published peer-reviewed primary comparative
studies (all comparative study designs for primary data
collection included; e.g., RCT, non-randomized trials,
cohort studies or case-control studies).
• Studycomparisonsincludeoneormoreofthefollowing:
– steroid therapy versus none.
– comparison of different doses of steroid therapy.
• Number of study participants with brain metastases C5
per study arm for at least two of the study arms.
• Baseline information on study participants is provided
by treatment group in studies evaluating interventions
exclusively in patients with brain metastases. For
studies with mixed populations (i.e., includes partici-
pants with conditions other than brain metastases),
baseline information is provided for the intervention
sub-groups of participants with brain metastases.
Study selection and quality assessment
Two independent reviewers evaluated citations using
a priori criteria for relevance and documented decisions in
standardized forms. Cases of disagreement were resolved
by a third reviewer. The same methodology was used for
full text screening of potentially relevant papers. Studies
which met the eligibility criteria were data extracted by one
reviewer and the extracted information was checked by a
second reviewer. The PEDro scale was used to rate the
quality of randomized trials [3, 4]. The quality of com-
parative studies using non-randomized designs was evalu-
ated using eight items selected and modiﬁed from existing
scales as outlined in Appendix B of the Methodology
chapter in this brain metastases guideline series [2].
Evidence classiﬁcation and recommendation levels
Both the quality of the evidence and the strength of the
recommendations were graded according to the criteria
endorsed by the American Association of Neurological
Surgeons (AANS) and the Congress of Neurological
Surgeons (CNS). These criteria are provided in the meth-
odology paper of this guideline series.
Guideline development process
The AANS/CNS convened a multi-disciplinary panel of
clinical experts to develop a series of practice guidelines on
the management of brain metastases based on a systematic
review of the literature conducted in collaboration with
methodologists at the McMaster University Evidence-
based Practice Center.
Scientiﬁc foundation
Despite the widespread use of steroids in the management
of brain metastases, only two publications met the stated
eligibility criteria [5, 6]. Figure 1 outlines the ﬂow of
studies through the review process. These two studies are
outlined in the attached evidentiary table. In order to
expand the information base for the ‘‘Discussion’’ section
of this chapter, additional searches were undertaken by
reviewing the bibliographies of these two papers and
additional review of the published literature addressing the
treatment of metastatic brain disease for references to
steroid administration. These articles are summarized in
the ‘‘Discussion’’.
Studies meeting search criteria
The only two papers that met the search criteria are sum-
marized below [5, 6]. The details are also summarized in
the accompanying evidentiary table (Table 1). In expand-
ing the literature review to seek out additional supporting
information for the ‘‘Discussion’’ portion of this document,
we did not encounter any additional high quality studies
speciﬁcally addressing the role of steroids in brain
Title and Abstract Screening 
n=16,966 
Full Text Screening 
n=2 
Excluded at Title and 
Abstract 
n=16,964 
Eligible Studies: 2 Included 
Steroid dosing regimes ……………..2  
Fig. 1 Flow of studies to ﬁnal number of eligible studies
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123metastases. This was in agreement with several previous
authors who upon review of the topic have encountered a
lack of detailed, controlled accounts of steroid use in the
studies under review, including the large randomized
controlled trials that often form the basis of treatment
decisions and recommendations [1, 7–9].
The ﬁrst of the two studies to meet the search criteria
described a randomized study of 4, 8 and 16 mg/day dosing
of dexamethasone and found no advantage to higher dosing
in patients who were not felt to be in impending danger of
cerebral herniation [5]. Vecht et al., published their ﬁndings
from two consecutively executed double-blind randomized
trials in patients with brain metastases and Karnofsky per-
formance scores (KPS) of 80 or less which were designed to
evaluatetheminimumeffectivedoseoforaldexamethasone.
Initiallyadexamethasonedosageof8 mg/day(Group1)was
compared to 16 mg/day (Group 2), followed by a compari-
sonof4 mg/day(Group3)versus16 mg/day(Group4).The
outcomes of interest were alteration in KPS and the fre-
quency of side effects at days 0, 7, 28, and 56.
In the initial study, although both groups showed an
improvement, there was no signiﬁcant difference in KPS
improvement comparing the 8-mg group versus the 16-mg
group at day 7 (mean 8.0 ± 10.1 versus 7.3 ± 14.2). At
the 28 day point, there was a larger but still non-signiﬁcant
rate of improvement thought to be biased by earlier steroid
tapering in the lower group.
In the second trial, again both groups showed
improvement. However, no signiﬁcant difference between
the 4- and 16-mg group (comparing 6.7 ± 11.3 points at
day 7 and 7.1 ± 18.2 points at day 28, versus 9.1 ± 12.4
and 5.6 ± 18.5 points, respectively) could be detected.
Side effects (Cushingoid changes and extremity edema)
occurred more frequently in the 16 mg/day versus the
4 mg/day group at Day 28 (Combined frequency 91%
versus 46%, P\0.03).
The authors conclude that for the majority of patients, the
lower doses of 4 and 8 mg dexamethasone per day have an
equivalent effect on improving neurologic performance
when compared to a dose of 16 mg/day at 1 and 4 weeks of
treatment, in moderately symptomatic patients without
signs of impending herniation. A non-signiﬁcant trend
toward improvement at 28 days was noted with the higher
dosage. The authors postulated that the early taper in the
lower dosage group led to an increase in recurrence of
symptoms that may have increased this apparent effect. The
dosing recommendation from this study resulted in a set
4 mg/day dosage with a dose taper for 28 days in patients
with no symptoms of mass effect used for the second study.
Side effects appeared to be dose-dependent, occurring
more frequently in patients using 16 mg/day. Therefore,
the authors concluded that steroid related toxicity was
increased with the higher daily dosage. Although the study
is double blind and randomized, the relatively small size,
inconsistencies in the design and lack of clarity in the
presentation of the data and analysis are concerns. None-
theless, this work appears to be the most detailed and
informative available to assist with formulating treatment
recommendations. The data, while extremely limited,
support a set of treatment recommendations which follow a
general trend toward higher steroid dosages in symptom-
atic patients exhibiting greater mass effect symptoms of
increased intracranial pressure, as opposed to lower doses
of steroids for asymptomatic patients.
Wolfson et al. [6] prospectively studied 12 patients with
histologically conﬁrmed malignancies and radiographically
documented brain metastases and attempted to evaluate the
indications for glucocorticoids. Patients were scored for
general performance status and neurologic function class.
All subjects received 24 mg of intravenous dexamethasone
every 6 h for 48 h and after an assessment, were random-
ized to receive either 4 mg of oral dexamethasone every
6 h (Group 1) or no steroids (Group 2) during radiotherapy
(30 Gy in ten fractions). Prior to randomization, ﬁve (33%)
had a positive response and eight (67%) had no response to
the high dose level. Seven patients were randomized to
continue receiving steroids at the reduced level and ﬁve
received none during radiotherapy. The change in general
performance status for Group 1 was: Improved 2/7 (29%),
deteriorated 1/7 (15%), no change 4/7 (57%). For Group 2,
the change in performance status was: Improved 0/5 (0%),
deteriorated 1/5 (20%) and no change 4/5 (20%). The
change in neurological function for Group 1 was: Improved
1/7 (14%), deteriorated 1/7 (14%), no change 5/7 (72%);
change in neurological function for Group 2 was: Improved
0/5 (0%), deteriorated 1/5 (20%), no change 4/5 (80%). No
statistical analysis was performed due to the small sample
size. The authors conclude that the speciﬁc role of steroids
in treating patients with metastatic carcinoma to the brain
remains uncertain and should be evaluated in a cooperative
prospective trial. Due to the small size and lack of any
statistical analysis, it is impossible to reach any conclusion
based on this study; therefore, no recommendations will be
made based on this small trial.
Discussion
Role of steroids in metastatic brain disease
Given the extremely limited number of studies which satis-
ﬁed the conditions of our search criteria, an additional dis-
cussion of published literature on the subject of
corticosteroids in metastatic brain disease is provided to
offer a larger context for this topic. While the following
studies were not part of the body of evidence considered in
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123formulating treatment recommendations in our evidence-
based guidelines, they do highlight areas of interest where
clinical trials are still required to answer important steroid-
related questions.
A review of the outcomes in the Radiation Therapy
Oncology Group (RTOG) studies examining various radi-
otherapeutic regimens for patients with metastatic brain
disease demonstrated a dramatic early improvement in
patients treated concurrently with steroids during the early
phases of the trials [10]. However, as the authors note, the
administration of steroids was not well controlled in these
studies and was not a primary point of interest so, although
these observations contributed to the overall clinical
impression that steroids were of beneﬁt in the adjuvant
treatment of brain metastases, it is difﬁcult to extrapolate
treatment recommendations from these studies. In Borgelt
et al., this is shown by the fact that symptomatic patients
receiving steroids had a signiﬁcant improvement in neu-
rological function as opposed to those who did not receive
steroids. None of these studies suggested that the use of
steroids halted time to progression.
Gaspar et al. [7] published an American College of
Radiology (ACR) Committee on Appropriateness Criteria
consensus report following an expert panel review on the
pre-irradiation evaluation and management of brain
metastases. The authors cite six articles to support the
generation of their expert opinions [5, 6, 10–13]. They
initially note that although clinical experience has estab-
lished the effectiveness of corticosteroids in reducing
symptoms and radiographic peritumoral edema, contro-
versy remains on the speciﬁc indications and dosage used.
They point out that the earliest studies to support steroid use
prior to radiotherapy used radiation dosing schemes that are
presently atypical and that there was evidence that steroids
were only indicated when there was a concern about raised
intracranial pressure [10–12]. In one study, 27% of patients
who received 10 Gy of single fraction whole brain radio-
therapy (WBRT) experienced signs of increased intracra-
nial pressure [12]. They also note evidence from one trial
indicating that patients who were moderately symptomatic
who received steroid therapy during radiation experienced a
more rapid improvement in their clinical symptoms,
although there was no impact on progression-free or overall
survival. This review went onto outline several papers
addressing the acute and chronic side effects and the studies
that address dosing and toxicity [5, 6, 13].
This consensus review summarizes the authors’ views
on steroid use for metastatic brain disease by indicating
that the patient who shows evidence of elevated intracra-
nial pressure, but who does not require immediate surgical
attention for either hydrocephalus or impending herniation,
should receive 4–6 mg/day of dexamethasone in divided
doses and that the routine use of corticosteroids in patients
without neurological symptoms is not necessary.
Effect of steroids on radiographic edema
In 1982, Hatam et al. [14] prospectively studied the effect
of dexamethasone therapy on peritumoral edema based on
computed tomography (CT) describing speciﬁcally three
cases of metastatic intracranial disease in which a linear
decrease in edema volume was observed, reducing the
measured volume of edema to one-fourth of the initial
volume after 2 weeks of treatment starting with 4 mg four
times daily and tapered to 1 mg/day. The exact time course
for the metastatic patients was not reported separately but
the authors did report a substantial clinical improvement in
these patients they felt was associated with the use of
dexamethasone.
Andersen et al. [11] published a subsequent report in
1994 that quantiﬁed the effect of steroid therapy over time
on peritumoral brain edema in vivo using a magnetic
imaging based technique. Magnetic resonance based
assessments of peritumoral edema were undertaken on 23
brain tumor patients including 13 with brain metastases at
baseline and at Days 1, 3 and 7 after starting steroid ther-
apy. Intravenous dexamethasone was used at dose of 0.26–
0.64 mg/kg (for a 70 kg patient this range is 20–45 mg/
day). After 7 days of steroid treatment the total edema area
was reduced by 10.3% in the metastatic patients, with an
average reduction in mean volume of 4.6% after 24 h of
treatment and 13.5% after 7 days. This effect was observed
for up to 63 days and it was demonstrated that after
40–63 days (6–9 weeks) of steroid therapy the peritumoral
water content was close to the upper normal range for
white matter. The authors concluded that steroids signiﬁ-
cantly reduce the volume of peritumoral edema in patients
with metastatic brain disease even after a few days of
treatment. They postulate a mechanism of steroid-induced
reduction in edema below the level of absorption and
commented that they thought they may have obtained the
same effects with a dose-reduction to minimize potential
side effects.
Minamikawa et al. [15] studied the effect of glucocor-
ticoid treatment (methylprednisolone, dose not speciﬁed)
on the apparent diffusion coefﬁcient (ADC) imaging in a
series of 13 patient including four with metastatic brain
disease. Although it is not possible to examine the effects
on the metastatic patients separately, the authors suggested
that ADC imaging was a more sensitive technique than
conventional MRI imaging for studying the effects of ste-
roids on peritumoral edema, even in the absence of
detectable MRI changes.
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Hempen et al. [13] retrospectively reviewed 138 consecu-
tive patients to evaluate the impact of dosage and duration
of dexamethasone administration during radiation therapy
for patients with both primary and metastatic brain tumors
(n = 91). The dosage of dexamethasone was gradually
reduced from an initial median dose of 7–12 mg/day to a
median of 1–6 mg/day with an average duration of 7 weeks
for the metastatic group. The authors reported a period of
initial clinical improvement with relatively few side effects.
Speciﬁcally, 33% of patients reported improvement in
symptoms with steroid use prior to radiotherapy, 44%
during radiotherapy and 11% following radiotherapy.
However, as dexamethasone was continued, this trend
reversed and less symptom relief was observed with
increasing toxicity. Life-threatening complications were
rare. Side effects attributed to steroid use included: hyper-
glycemia (47%), peripheral edema (11%), psychiatric dis-
order (10%), candidiasis (7%), Cushing’s syndrome (4%),
muscular weakness (4%) and pulmonary embolus (2%). Of
a cohort of 13 clinically asymptomatic patients who
received no dexamethasone during radiotherapy, 12 (92%)
showed no sign of worsening neurological problems. The
patient with worsened symptoms had brain stem involve-
ment. The authors conclude that dexamethasone effectively
minimizes neurological symptoms and radiation therapy
related side effects in patients with both primary and sec-
ondary brain tumors. The toxicity of dexamethasone was
noted to increase over time and therefore a patient-speciﬁc
dosing pattern and taper was recommended. The authors
suggested that a prospective study speciﬁcally addressing
the relative balance of symptom relief versus toxicity would
be of beneﬁt and that there is little evidence to support the
use of steroids in the asymptomatic patient.
In 1999, Lagerwaard et al. [8] published an extensive
retrospective review of 1,292 patients with metastatic brain
disease referred to a single institution to identify prognostic
(risk) factors. The majority of patients were treated with
WBRT (n = 1,079, 84%); 118 (9%) were treated with
steroids only and 95 (7%) with surgery and radiotherapy.
Data obtained included: age, sex, performance status,
number and distribution of brain metastases, site of primary
tumor, histology, interval between primary tumor and brain
metastases, systemic tumor activity, serum lactate dehy-
drogenase, response to steroid treatment, and treatment
modality. Dexamethasone was used in a dose range of 4–
16 mg/day (mean dosage 14.6 mg/day), which was
‘‘tapered slowly and discontinued in the weeks following
therapy’’ (speciﬁc details not stated).
Response to steroid therapy was judged retrospectively,
from review of the medical records, as good (marked
improvement), moderate (some improvement) or little
(little or no improvement). Both univariate and multivari-
ate analyses were performed. The overall median survival
was 3.4 months, with 6 month, 1, and 2 year survival
percentages of 36, 12, and 4%, respectively. Median sur-
vival was 1.3 months in patients treated with steroids only,
3.6 months in patients treated with radiotherapy, and
8.9 months in patients treated with surgical resection fol-
lowed by radiotherapy (all comparisons P\0.0001).
Multivariate analysis conﬁrmed the previously reported
observation that the impact of treatment modality on sur-
vival in patients with brain metastases was the most sig-
niﬁcant single factor in predicting survival. However,
response to steroid treatment, performance status, systemic
tumor activity and serum lactate dehydrogenase levels
were also all independent prognostic factors on survival,
second only to treatment modality in level of signiﬁcance.
Site of primary tumor, age, and number of brain metastases
were also identiﬁed as prognostic factors.
The authors concluded that the strongest prognostic
(risk) factors were choice of treatment modality, response
to steroids, performance status, and evidence of systemic
disease and they proposed using these classiﬁers in iden-
tifying favorable and unfavorable subgroups of patients
with brain metastases for future studies.
Millar et al. [9] attempted to assess the impact of steroid
therapy in the management of brain metastases by under-
taking a systematic review of published randomized trials
on WBRT for multiple cerebral metastases. In this exten-
sive review published in 2004, the authors identiﬁed 21 full
manuscripts of published randomized controlled trials
involving WBRT in the treatment of multiple brain
metastases from 1971 to 2003. They attempted to extract
details on the use and type of steroid, timing of steroids
relative to radiotherapy, response assessment and contri-
bution of steroids to overall outcome. They reported that 18
of the 21 trials reviewed documented steroid use. Overall
survival was an outcome assessed in all studies. Thirteen
studies assessed neurological response and ten assessed a
radiographic endpoint. Ten of the studies (48%) suggested
a positive effect of steroid use on the outcome assessed.
Only one study—in the palliative setting—provided a ﬁxed
steroid dose.
The authors concluded that the reporting of steroid use
in previously published randomized trials assessing treat-
ment for patients with brain metastases is ‘‘non-uniform
and not sufﬁciently detailed’’ making it difﬁcult to assess
the treatment effect. They call for a more standard
approach to steroid dose in future studies or at a minimum
better reporting of dosages used to better determine
symptom response and durability of response. They also
note that side effects of steroid use and the ability to taper
off steroids after treatment intervention are additional
outcomes of interest in the planning of future studies.
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treatment regimen designed to reduce steroid toxicity in 20
patients with newly diagnosed brain metastases. All
patients received dexamethasone starting at 8 mg twice
daily for 4 days then 4 mg twice daily for 4 days followed
by 2 mg twice daily until the last day of radiation therapy.
Radiation dose and schedules ranged from 20 Gy in ﬁve
fractions to 58 Gy in 29 fractions. Fourteen patients (70%)
received dexamethasone for a minimum of 24 h before
their ﬁrst radiation treatment and seven of those patients
(50%) experienced improvement in neurologic symptoms
and signs before radiotherapy. Fourteen patients (70%)
completed the entire course of radiation and dexametha-
sone as planned. One patient required reinstitution of
dexamethasone within 30 days of ﬁnishing radiation for
neurological decline. The authors felt that the twice-daily
dose was well tolerated. Steroid related toxicity included
hyperglycemia (5%), candida esophagitis (5%), steroid
pseudorheumatism (10%), peripheral edema (5%) and
steroid withdrawal syndrome (5%).
In 2006, the results of a series of systematic reviews with
the stated purpose ‘‘to establish evidence-based guidelines
and identify controversies regarding the management of
patients with brain metastases’’ was published by Sofﬁetti
et al. [1]. This was conducted by a multi-disciplinary task
force of the European Federation of Neurological Societies
and includes a review of data obtained from the Cochrane
Library, bibliographic databases, overview papers and pre-
vious guidelines from scientiﬁc societies and organizations.
Under the section on supportive care and steroids only one
original article is cited and reviewed, and that is the publica-
tionbyVecht[5],whichalsomettheeligibilitycriteriaforthis
guideline paper and is discussed extensively in the scientiﬁc
foundation section. This paper was used to support the rec-
ommendationthat,inmostcases,initialdexamethasonedoses
should not exceed 4–8 mg/day. However, in patients with
more severe symptoms related to increased intracranial
pressure doses of 16 mg/day or higher should be considered
(Level of Evidence B) [17]. The remainder of the recom-
mendationswerebasedonuniformconsensusofthetaskforce
(referredtoasa‘‘GoodPracticePoint’’)andaresummarized
below. Dexamethasone was noted as the corticosteroid of
choice and twice daily dosing was thought to be sufﬁcient
(Good Practice Point). Tapering of steroid dosing within
1 week of starting therapy and discontinuation within
2 weeks if possible was encouraged (Good Practice Point).
Finally, patients who do not have signs or symptoms of
increasedintracranialpressuredonothave tobetreatedwith
steroids (Good Practice Point).
Given the very limited number of studies that met the
inclusion criteria for the systematic literature review on the
role of steroids in metastatic brain disease, we are unable to
propose speciﬁc guidelines on many of the issues of central
interest to the treating physician.
In summarizing the Discussion section above we are
able to offer the following observations: ﬁrst, Overall the
literature favors the position that corticosteroids are of
beneﬁt in providing temporary symptomatic relief of CNS
symptoms related to increased intracranial pressure and
edema secondary to brain metastases [1, 7–10, 13]. Sec-
ondly, dexamethasone is the steroid most often used, with
the rationale that it has limited mineralocorticoid effects.
Other steroids have been used with similar reported clinical
responses. Dosing has been recommended to be sufﬁcient
at twice daily although more frequent dosing has been
suggested with increasing concern for raised intracranial
pressure and impending herniation [1, 7, 8, 11, 14]. Finally,
based primarily on the asymptomatic patients in the study
by Hempen et al., it is the opinion offered in the available
studies that asymptomatic patients do not require steroids
[1, 7, 13]. Numerous authors cite concerns for the toxicity
of steroid therapy and due to the lack of a uniform rec-
ommendation on dosing and the apparent complexity of the
response in individual patients it has been recommended
that dose reduction be considered within 1 week of initia-
tion of treatment. The dose reduction appears to often
require alteration in individual patients due to the diversity
of response [1, 7, 9, 13, 16].
An interesting observation in the review of the literature
on this subject is the number of authors who appear to
assume that steroids are a mainstay of treatment for the
patient with metastatic brain disease despite the relative
lack of detailed information available to guide speciﬁc
therapy. In general, the evidence for speciﬁc dosages and
regimens of steroids are poorly detailed. On the other hand,
there is very little information provided in the literature
that suggests that steroids are of no beneﬁt in this patient
population with the exception of the asymptomatic patient.
Given the general consensus in the literature that ste-
roids are of beneﬁt in selected patients with metastatic
brain disease and the frequent observation that dosing
needs to be speciﬁcally tailored to the individual, it appears
unlikely that in depth studies speciﬁcally addressing this
issue will be forthcoming. However, the need for additional
recommendations for dosing and duration of therapy may
result in an increased awareness of this concern and
potentially an alteration of clinical trials designed to
address comparisons.
Summary and conclusions
In terms of articles meeting the search criteria described in
the methods section above, the study by Vecht et al. [5]
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role for steroids in patients with brain metastases and for
the choice of dosing. Based on their observations of
improvement in all groups treated with steroids, a level 3
recommendation can be made as follows:
Steroid therapy versus no therapy
Corticosteroids are recommended to provide temporary
symptomatic relief of CNS symptoms related to increased
intracranial pressure and edema secondary to brain
metastases. (Level 3 recommendation). Dexamethasone is
the corticosteroid of choice, mainly because of its limited
mineralocorticoid effects, and should be tapered slowly
over several weeks to avoid rebound symptoms.
The Vecht et al. [5] article provides evidence that the
administration of steroids provides relief of symptoms in
patients with symptomatic brain metastatic disease; how-
ever, recognizing that there is no control group (a ‘‘no
treatment group’’) only the lowest grade of recommenda-
tion can be made.
Vecht et al. [5] also conclude that a starting dose of
4–8 mg/day be considered, unless patients exhibit severe
symptoms consistent with increased intracranial pressure.
They further recommended that those patients at high risk
for severe consequences from raised intracranial pressure
be considered for more aggressive dosing on the order of
doses of 16 mg/day or higher. This study is relied upon
heavily in the systematic review and consensus reports
summarized in the ‘‘Discussion’’ section above [1, 7, 9].
However, the number of patients involved is relatively
small and the study lacks a validation group; thus, despite
the randomized design and ranking yielding a higher class
of evidence, the recommendation itself is downgraded to
reﬂect these concerns. Based on this study design and
results, the following recommendation can be made.
Comparison of different doses of steroid therapy
It is recommended for patients who are symptomatic from
metastatic brain disease that a starting dose of 4–8 mg/day
of dexamethasone be considered, unless patients exhibit
severe symptoms consistent with increased intracranial
pressure. In these patients it is recommended that higher
doses such as 16 mg/day or more be considered. (Level 3
recommendation)
Key issues for further investigation
Given the number of patients who receive steroids as a
portion of their care for treating the signs and symptoms of
brain metastases, the medical literature contains relatively
few detailed reports speciﬁcally addressing this issue. It
may be that the early observation that there was little effect
on overall survival has limited the subsequent level of
interest in this issue. Review of the literature ﬁnds that the
majority of authors on the subject feel that there is a
symptomatic beneﬁt from the use of systemic steroids in
the management of these patients. It is not clear that there
is an urgent need for randomized trials speciﬁcally
addressing the issue of steroid dosing and toxicity. How-
ever, future studies could be planned to allow better con-
trol, recording and analysis of steroid dosing and response
to allow a more robust analysis of the risk to beneﬁt ratio of
various dosing regimens. This would potentially optimize
the beneﬁts while limiting the side effects, which could
lead to an improvement in overall outcome in addition to
improving quality of life measures in the short term.
No ongoing or recently closed clinical trials on the
use of steroids for the management of brain metas-
tases were found that met the eligibility criteria.
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